Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd (BLISSGVS) last reported results for the quarter ended Jun 2026, with sales of ₹286 crore and net profit of ₹51 crore. The stock last traded at ₹656, a market capitalisation of ₹6,937 crore, on a P/E of 50.4. Over the past 52 weeks the stock has ranged between ₹118 and ₹745. Figures are as of 9 Oct 2026 and are not real time.
Bliss GVS Pharma Ltd share price and key metrics
- Current price
- ₹656
- Market cap
- ₹6,937 cr
- Stock P/E
- 50.4
- Book value
- ₹113
- ROE
- 11.8%
- ROCE
- 16.9%
- Dividend yield
- 0.23%
- 52w high / low
- 745/118
Metrics as of 9 Oct 2026. Not real time.
Track Bliss GVS Pharma Ltd
Cruxal reads every Bliss GVS Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Bliss GVS Pharma Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 10%
- 3 Years
- 7%
- TTM
- 21%
- 10 Years
- 5%
- 5 Years
- 14%
- 3 Years
- 23%
- TTM
- 29%
- 10 Years
- 16%
- 5 Years
- 42%
- 3 Years
- 95%
- 1 Year
- 316%
- 10 Years
- 11%
- 5 Years
- 9%
- 3 Years
- 10%
- Last Year
- 12%
Bliss GVS Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹286 cr, up 38.2% from ₹207 cr a year earlier. Net profit was ₹51 cr, up 15.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 218 | 210 | 198 | 207 | 244 | 218 | 257 | 286 |
| Expenses | 176 | 181 | 177 | 166 | 201 | 183 | 213 | 209 |
| Operating profit | 41 | 30 | 21 | 41 | 43 | 35 | 44 | 76 |
| OPM % | 19% | 14% | 11% | 20% | 18% | 16% | 17% | 27% |
| Other income | 5 | 15 | 12 | 35 | 8 | 16 | 11 | 10 |
| Interest | 4 | 1 | 2 | 5 | 3 | 1 | 2 | 1 |
| Depreciation | 7 | 8 | 8 | 8 | 8 | 8 | 9 | 10 |
| Profit before tax | 36 | 36 | 23 | 63 | 41 | 41 | 45 | 75 |
| Tax % | 28% | 29% | 29% | 30% | 30% | 39% | 18% | 32% |
| Net profit | 26 | 26 | 17 | 44 | 29 | 25 | 37 | 51 |
| EPS (₹) | 2.31 | 2.26 | 1.47 | 4.08 | 2.58 | 2.20 | 3.36 | 4.72 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Bliss GVS Pharma Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 927 | 1,005 |
| Operating profit | 203 | 197 | 160 | 123 | 107 | 118 | 117 | 151 | 127 | 168 | 199 |
| OPM % | 25% | 24% | 18% | 18% | 18% | 16% | 16% | 20% | 16% | 18% | 20% |
| Net profit | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 135 | 142 |
| EPS (₹) | 7.95 | 5.70 | 11.99 | 9.43 | 6.64 | 1.45 | 6.80 | 7.21 | 8.00 | 12.21 | 12.86 |
TTM is the trailing twelve months to the most recent quarter.
Bliss GVS Pharma Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 |
| Reserves | 476 | 526 | 636 | 725 | 798 | 808 | 873 | 957 | 1,040 | 1,182 |
| Borrowings | 225 | 118 | 102 | 126 | 122 | 109 | 102 | 100 | 88 | 22 |
| Other liabilities | 311 | 206 | 157 | 168 | 147 | 181 | 171 | 145 | 163 | 278 |
| Total liabilities | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 | 1,492 |
| Fixed assets | 305 | 143 | 146 | 242 | 234 | 281 | 379 | 370 | 406 | 459 |
| CWIP | 4 | 0 | 47 | -0 | 2 | 22 | 3 | 8 | 21 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 | 4 | 5 |
| Other assets | 714 | 717 | 712 | 788 | 840 | 803 | 768 | 830 | 871 | 1,022 |
| Total assets | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 | 1,492 |
As reported by the company. Total assets equal total liabilities by construction.
Bliss GVS Pharma Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 289 | 18 | 40 | 47 | 64 | 135 | 34 | 103 | 106 | 139 |
| Cash from investing | -249 | 48 | -79 | -40 | -45 | -103 | -6 | -83 | -75 | -38 |
| Cash from financing | -10 | -76 | 17 | -6 | -21 | -24 | -25 | -21 | -30 | -89 |
| Net cash flow | 30 | -10 | -22 | 0 | -2 | 9 | 3 | -1 | 0 | 11 |
| Free cash flow | 186 | -7 | 2 | -12 | 55 | 63 | -59 | 75 | 33 | 84 |
| CFO / operating profit | 160% | 29% | -8% | 69% | 87% | 143% | 67% | 91% | 112% | 108% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Bliss GVS Pharma Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 29% | 27% | 26% | 18% | 12% | 14% | 12% | 14% | 12% | 17% |
| Debtor days | 116 | 134 | 187 | 290 | 293 | 192 | 187 | 192 | 198 | 204 |
| Inventory days | 50 | 55 | 46 | 64 | 110 | 116 | 94 | 113 | 111 | 129 |
| Days payable | 100 | 55 | 47 | 75 | 82 | 86 | 79 | 58 | 63 | 89 |
| Cash conversion cycle | 67 | 134 | 186 | 279 | 321 | 221 | 202 | 247 | 246 | 244 |
| Working capital days | -10 | 135 | 154 | 232 | 264 | 179 | 192 | 207 | 198 | 214 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Bliss GVS Pharma Ltd shareholding pattern
Promoters held 35.01% at Jun 2026, broadly unchanged since Jun 2025. FIIs 8.07% and DIIs 9.46%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 34.82% | 35.10% | 35.29% | 35.44% | 35.39% | 35.36% | 35.36% | 35.01% |
| FIIs | 12.13% | 13.51% | 13.18% | 12.65% | 13.27% | 14.54% | 10.45% | 8.07% |
| DIIs | 6.56% | 6.55% | 6.55% | 6.54% | 5.98% | 5.78% | 5.04% | 9.46% |
| Public | 46.49% | 44.84% | 44.98% | 45.37% | 45.36% | 44.32% | 49.15% | 47.45% |
| No. of shareholders | 52,937 | 49,558 | 49,517 | 46,707 | 44,461 | 43,380 | 44,874 | 46,767 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find enclosed herewith the certificate under Regulation 74(5) of SEBI(DP)…
Read the full analysis - Catalyst Trusteeship Limited pledges 47.95% of equity shares of Bliss GVS Pharma Limited via debt security encumbranceInsider Trading / SASThigh impact
Cruxal's analysis: Catalyst Trusteeship Limited has disclosed a pledge over 47.95% of Bliss GVS Pharma…
Read the full analysis - Board Approves Employee Stock Option Plans, Granting Up to 73.5 Lakh Shares Pending Shareholder ApprovalBoard Meetingmedium impact
Cruxal's analysis: Bliss GVS Pharma Limited has announced the approval of two new employee stock option…
Read the full analysis - Regulatory Disclosure Reveals Major Share Acquisition by Anupam Rasayan India Limited in Bliss GVS Pharma Limited, Increasing Stake to 50.07%Insider Trading / SASThigh impact
Cruxal's analysis: Indian specialty chemicals company Anupam Rasayan India Limited has disclosed a…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find enclosed herewith the Intimation for the Closure of the Trading Window w.e.f…
Read the full analysis - Bliss GVS Pharma to consider new Employee Stock Option Plans (ESOP 2026) in upcoming board meetingBoard Meetinglow impact
Cruxal's analysis: Bliss GVS Pharma Ltd. has announced a board meeting scheduled for October 01, 2026, to…
Read the full analysis - Bliss GVS Pharma Limited Announces Completion of Promoter Change and Reclassification to Public CategoryCompany Updatemedium impact
Cruxal's analysis: Bliss GVS Pharma Limited has officially confirmed the consummation of the share purchase…
Read the full analysis - Bliss GVS Pharma Ltd. Announces Change in Control and Promoter Status Following Acquisition by Anupam Rasayan India LimitedCompany Updatehigh impact
Cruxal's analysis: Bliss GVS Pharma Ltd. has officially confirmed a change in control and promoter status…
Read the full analysis - Bliss GVS Pharma Limited shareholders approve appointment of Santosh Parab as Non-Executive, Non-Independent DirectorAGM/EGMlow impact
Cruxal's analysis: Bliss GVS Pharma Limited has successfully concluded its postal ballot process, with…
Read the full analysis - Bliss GVS Pharma Limited: Post-Offer Advertisement confirms minimal public participation in open offerCompany Updatelow impact
Cruxal's analysis: Bliss GVS Pharma Limited has issued a post-offer advertisement following the open offer…
Read the full analysis - Bliss GVS Pharma Ltd announces extension of special window for physical share re-lodgementCompany Updatelow impact
Cruxal's analysis: Bliss GVS Pharma has published a newspaper notice regarding the extension of the special…
Read the full analysis - Bliss GVS Pharma Ltd publishes newspaper advertisement for Postal Ballot NoticeCompany Updatelow impact
Cruxal's analysis: Bliss GVS Pharma Ltd has completed the mandatory regulatory requirement of publishing a…
Read the full analysis - Bliss GVS Pharma Limited initiates postal ballot for appointment of Mr. Santosh Parab as Non-Executive Non-Independent DirectorAGM/EGMlow impact
Cruxal's analysis: Bliss GVS Pharma Limited has issued a notice of postal ballot to seek shareholder…
Read the full analysis - Bliss GVS Pharma Reports Strong Q1 FY27 Consolidated Net Profit of 51.37 crore, Reflecting Robust YoY GrowthCompany Updatehigh impact
Cruxal's analysis: Bliss GVS Pharma Limited has announced its unaudited financial results for the quarter…
Read the full analysis - Bliss GVS Pharma grants 320,000 stock options under ESOP 2019Company Updatelow impact
Cruxal's analysis: The Nomination and Remuneration Committee of Bliss GVS Pharma Limited approved the grant…
Read the full analysis - Bliss GVS Pharma Reports Q1 FY27 Financial Results with Consolidated Net Profit of 51.37 CroreBoard Meetinghigh impact
Cruxal's analysis: Bliss GVS Pharma Limited reported its unaudited financial results for the quarter ended…
Read the full analysis - Bliss GVS Pharma Ltd allots 31,250 equity shares under ESOP 2019Company Updatelow impact
Cruxal's analysis: Bliss GVS Pharma Ltd has approved the allotment of 31,250 equity shares with a face value…
Read the full analysis - Life Insurance Corporation of India (LIC) reduces stake in Bliss GVS Pharma Ltd to 2.959%Insider Trading / SASTlow impact
Cruxal's analysis: Bliss GVS Pharma Ltd has received a disclosure under SEBI Regulation 29(2) indicating…
Read the full analysis - Bliss GVS Pharma Limited schedules Board Meeting for August 12, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Bliss GVS Pharma Limited has formally intimated the stock exchanges regarding a Board of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.